Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
2p plus and more on its way, Final Results expected soon and every chance Eric will have an update or two on proceedings. Excitement building!!! Gl :-)
Hopefully someone in the know Porter. :-)))
Share accumulation in progress!!! Gla :-)
Looking forward to the Merry month of May!!! Gla holders, a significant re-rate beckons imho.....On and UP!!! :-)
Three of us!!! :'-)))
A very nice 650k buy just in at 1.9p!!! Gla :-)
News on patents, progress on pipeline, US investors, collaborators etc at anytime, but we're still awaiting Final reports from the 4 invivo studies to be officially published, which could be highly significant, although not sure if they're already in the mix as we progress to human clinical trials, or if there's going to be a peer-review or similar scientific publication, but Vera's podcast is well worth a listen as she goes into great depth of the studies they're carrying out on Sirt6, and interestingly enough, Vera hasn't published any news at all from her lab, so far this year???.Gla :-)
September 2023
The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.
These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.
........
A fascinating and insightful Podcast interview with Vera Gorbunova from 24/10/23 discussing the promising potential for Sirt6 and how she is conducting indepth research in collaboration with Biotech companies, and confirms results should be available in a few months. Gla :-)
SIRT6 The Science Behind The Longevity Gene | Professor Vera Gorbunova Ep1
Oct. 24, 2023
htTps://www.listennotes.com/podcasts/modern-healthspan/sirt6-the-science-behind-the-Z8u9qApmey_/
Not long now before sub 2p will be a distant memory with any luck, a major re-rate or two highly likely with plenty of significant positive newsflow stacking UP!!! Gla :-)
Couldn't agree more Dave, ridiculously undervalued but our fortunes could change in a blink, and yes indeed Porter, along with the recent institutional investors, many pi's are appreciating the opportunity ahead. Final Results expected now which will outline prospects and potential and solid cash position , and more good news in the pipeline for full market appreciation and investor interest at anytime. Gla ....On and UP!!! :-)
Looking good and strong, very low free float with the majority of shares held for greater things to come and so any good news should see a solid and significant re-rate. Gla holders, Momentum building, Genflow is all set for a stellar year ahead imho. ;-)
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,585 followers
23m
🧬 Genflow Biosciences has an updated presentation! 🧬
To learn more about the cutting-edge #biotech research & studies currently underway, as well as Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s strong investment thesis, click here: hTtps://loom.ly/qLRb1jE
#SIRT6 #GENF #NASH #aging #healthspan
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,585 followers
18h
Safety paramount in the #biotech industry, and at Genflow Biosciences (LON:GENF) (OTCQB:GENFF), it's our top priority. We're proud to have developed patent-pending technology to enhance safety in our #SIRT6 studies.
It is this unwavering commitment to safety that has allowed us to advance a number of our studies to the pre-clinical/development stage, including treatments for diseases ranging Werner Syndrome to #NASH.
Learn more about Genflow's innovative studies & exciting investment thesis: https://lnkd.in/eYJ_AQ3H
#GENF #aging #healthspan #NASH #genetherapy
Investors – Genflow Bioscience
Cutting edge science with patents pending, compelling preclinical data progressing to human clinical trials, prestigious academic partners and a leading influential and distinguished hands on Scientific Advisory Board, at least c£4m plus cash in the bank and a market cap of £4.5m.
Exponential upside potential and prospects!!!
Will a Major Pharma/JV partner wait for positive trial results from Genflow's Nash Human Clinical Phase 1/2 trials planned for next year, or will one move early given how hot the Nash/Liver space is right now, as well as the promise of a rapidly expanding and evolving longevity market and the compelling nature of SIRT6's profound importance and influence over multiple disease targets associated with aging.
Exciting times!!! Gla holders :-)
Acknowledgements
We thank Dr. Lin Gan from the Institutional Mouse Transgenic Core Facility at the University of Rochester for generating the Sirt6 transgenic mice.
Published: 22 April 2024
Hepatic Sirt6 activation abrogates acute liver failure
Discussion
In this work, we revealed a crucial role of Sirt6 in protecting against both APAP-induced and BDL-induced ALF. Our investigation has begun from an interesting observation that hepatic Sirt6 expression significantly downregulated in the livers of human and mice with acute liver failure. The rescue and maintenance of Sirt6 expression in the Sirt6-Tg mice after APAP administration protected against the pathological changes during APAP-induced liver toxicity by limiting oxidative stress and inflammation. The protective effect of hepatic Sirt6 was further validated in Sirt6-HepTg mice and in the mice treated with the specific Sirt6 activator MDL-800. Hepatic-specific Sirt6 knockout in mice exacerbated, but hepatic overexpression of Sirt6 ameliorated, acute liver damages-induced by both APAP and BDL. Furthermore, the Sirt6 activator MDL-800 presented better therapeutic potential to alleviate liver injury in mice than NAC, which is the only proved antidote for APAP overdose up to now. Taken together, these results demonstrate that Sirt6 could be an important therapeutic target for the treatment of ALF.
..............
In conclusion, our results revealed a crucial role of hepatic Sirt6 in the protection of acute hepatotoxicity. Genetic overexpression of Sirt6 and the pharmacological activation of Sirt6 ameliorated oxidative stress, inflammation, and liver injury. The potential mechanisms whereby Sirt6 protects against hepatotoxicity include that Sirt6 inhibits JNK and caspase 3/9 activation, enhanced Nrf2/HO-1 pathway and attenuates PARP1 expression and activity. Therefore, Sirt6 orchestrates the safeguard against hepatotoxicity and may serve as a new therapeutic target for the ALF.
hTtps://www.nature.com/articles/s41419-024-06537-5
The liver is the only organ that can regrow and repair itself and Ochre Bio will seek to develop drugs that restore this ability in diseased livers.
The company’s work to date has involved analysing thousands of donated human livers to develop an understanding of the causes of disease, and studying whether making changes to RNA — a vital molecule for translating genetic information into proteins — can extend the lifespan of transplanted livers.
“What we’re trying to do is give the liver a little nudge in the right direction to support it to regenerate,” said Quin Wills, chief scientific officer and co-founder of Ochre Bio. “What happens in a cirrhotic liver is [cells] don’t have that decision-making process any more to start dividing and restoring capacity. By changing certain ‘switches’, using these RNA therapies, we help them make those decisions again.”
There have been a series of recent developments in the treatment of liver disease, which is the third-largest cause of early death in the UK and other high-income countries. It is also the largest killer of 35- to 49-year-olds in the UK, according to the UK Health Security Agency.
The US Food and Drug Administration recently approved the first-ever drug designed specifically for the most common liver disease, metabolic dysfunction-associated steatohepatitis or mash, developed by Madrigal Pharmaceuticals.
People with mash have a build-up of fat deposits in the liver and it is estimated to affect 115mn people worldwide. The approval of Madrigal’s drug should help other treatments to pass regulatory hurdles, according to analysts at investment bank William Blair.
The disease is often linked with weight gain and has become more common as obesity levels have risen.
Pharma groups are optimistic about the potential for new weight loss and diabetes drugs known as GLP-1s to treat liver diseases.
A weight-loss drug licensed by Boehringer Ingelheim from Danish biotech Zealand Pharma has had positive results in liver disease trials, while Novo Nordisk is looking at the effect of its weight-loss drug Wegovy on mash.
But while these drugs could be used to treat early-stage disease, the industry thinks they will be less helpful against more advanced mash, which can involve extensive scarring or cirrhosis of the liver. New ways of tackling late-stage liver disease could delay the need for transplants, currently the only effective treatment.
Jack O’Meara, chief executive of Ochre Bio, told the Financial Times: “There still remains a huge unmet need there and we hope this partnership with Boehringer will be able to develop medicines that solve or offer solutions for patients at a later stage.”
Søren Tullin, head of cardiometabolic disease research at Boehringer Ingelheim, said Ochre Bio’s genomics experience and technology “holds the potential to uncover novel regenerative pathways that will make a meaningful difference in the lives of those a
UK biotech signs $1bn deal to develop liver disease drugs
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/3cd4fc3c-e52b-4042-9540-08ce2444b5bd
German pharma group Boehringer Ingelheim has struck an up to $1bn partnership with a UK biotech to develop treatments for chronic liver disease that aim to harness the organ’s capacity to regenerate.
Under the drug discovery partnership, Ochre Bio will receive $35mn in upfront and near-term payments, rising to more than $1bn in payments and royalties if treatments are successfully brought through clinical trials. It is a similar milestone-based structure to many partnerships in the pharmaceutical industry.
https://www.ft.com/content/3cd4fc3c-e52b-4042-9540-08ce2444b5bd
Regeneron launches five-year $500m biotech fund
1 HOUR AGO
Biopharma giant commits $100m annually to Regeneron Ventures as it seeks to ‘fuel promising biotech innovation.’
Yesterday, as we revealed 2023 was another tough year for longevity investment, biotech heavyweight Regeneron quietly announced the formation of Regeneron Ventures, a new $500 million venture capital fund. As the fund’s exclusive limited partner, Regeneron has pledged $100 million annually over the next five years to invest in promising life sciences companies.
While the new fund’s investment mandate is broadly health focused, Regeneron Ventures says its interest is “skewed towards biotechnology, devices, tools, and enabling technologies.” The fund says that investment decisions will be guided by the quality of the science, people, and data, prioritizing “breakthrough innovation” despite the inherent risks and uncertainties. All of which should resonate well with founders in the longevity sector, offering a potential new source of funding for biotech startups targeting aging and age-related diseases.
htTps://longevity.technology/news/regeneron-launches-five-year-500m-biotech-fund/amp/
SIRT6 is an enzyme that plays an essential role in human health and contributes to epigenetic regulation of gene expression, mitochondrial health, and DNA repair. A review of literature suggests that SIRT6 could potentially help address diseases of aging, neurodegeneration, diabetes and obesity, in addition to depression. Arrivo is exploring the potential of SP-624 in multiple therapeutic areas beyond depression.
Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator
Epigenetic mechanism of action offers a promising new approach to tackling MDD
April 16, 2024 08:00 AM Eastern Daylight Time
MORRISVILLE, N.C.--(BUSINESS WIRE)-
-Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
htTps://www.businesswire.com/news/home/20240416487796/en/Arrivo-Bio-Initiates-Large-Phase-2b-Clinical-Trial-in-Major-Depressive-Disorder-with-Novel-SIRT6-Activator